Will we-the-quails unite to lift the net or wither away the gains made in AIDS response? By SHOBHA SHUKLA, BOBBY RAMAKANT ...

Participants who initiated long-acting cabotegravir-rilpivirine had a high rate of adherence and virologic suppression, with ...

Experts have proposed new treatment modes for older people with HIV. The new treatment does not cause the health-threatening ...

WHO recommends twice-yearly injectable lenacapavir for HIV prevention, expanding PrEP options for key populations.

For more than two decades, the global community has united to fight the HIV pandemic, achieving remarkable progress. New HIV transmissions and AIDS-related deaths have dropped significantly, and ...

The investigational oral pre-exposure prophylaxis (PrEP) agent MK-8527 showed a similar, well-tolerated safety profile to placebo, with dose-proportional pharmacokinetics, among adults with a low ...

Newsday Zimbabwe HEALTH and Child Care minister Douglas Mombeshora has reaffirmed the country’s commitment to advancing HIV research, treatment and global collaboration. He said this during the ...

Researchers wanted to provide insight into the relative clinical value of Apretude and lenacapavir compared with no ...

After the virologic failure of cabotegravir/rilpivirine and despite dual-class resistance mutations, Canadian doctors have ...

However, despite the Senate's decision to protect Pepfar from President Trump's proposed $400 million (Sh51.6 billion) ...

A decade ago, the global community established the goal to end AIDS as a public health threat by 2030 through reducing new HIV infections and AIDS-related deaths by 90% from 2010 levels.1 Progress has ...

Integrating people-centered HIV care with primary health care is essential to improving access, equity and health outcomes, but doing so successfully requires coordinated policies, digital ...